BARDA’s Portfolio of Medical Countermeasures for Novel Coronavirus
To date, BARDA has built an impressive portfolio for novel coronavirus medical countermeasures. This portfolio consists of 33 companies developing a variety of measures ranging from diagnostics to vaccines, therapeutics, and more.
For vaccine development alone, BARDA has awarded over $2.1B to companies, including Moderna and AstraZeneca, both of which have recently shown promising vaccine candidates. A further $21M+ has been awarded to companies developing diagnostic candidates, with an emphasis on rapid testing and diagnosis capabilities. Over $310M has been awarded for therapeutic candidates, including companies utilizing plasma from recovered patients. Other companies that don’t fall into these three categories have been awarded a total of $42M+.
For a complete list of companies and award fees, click here